ECOR$8.27+14.38%
electroCore, Inc.
Sector: Electromedical & Electrotherapeutic ApparatusIndustry: Medical - DevicesCountry: USExchange: Nasdaq
Mkt Cap:$74.73M
Float & O/S:
Inst Own:11.9%
DilutionScan read 32 of electroCore, Inc.'s SEC filings and found 6 warrant series, 1 convertible, 1 ATM program, 3 shelf registrations and 1 completed offering on file for ECOR. The latest dilution event on file is ATM sales on Aug 6, 2026. Analysis updated Oct 7, 2026.
Signal8 Summary
6d old
ECOR
Going-concern warning, cash-strapped micro-cap
- Business
- WeakGoing-concern doubt, 4.6-month runway, $14M net loss
- Stock risk
- High$76.6M micro-cap, shares +13.4% YoY, 40.8% potential dilution
Snapshot
electroCore is a small medical-device maker growing revenue fast, $32.0M in FY 2025, up 27.2%, with a strong 86.8% gross margin, but it still lost $14.0M and burned $8.3M in free cash flow. Cash sits at only $10.0M against $9.6M of debt, and Signal8 models roughly 4.6 months of runway.
What's Happening Right Now
- : electroCore will report third-quarter 2026 results after market close on Nov 4, 2026, with a conference call the same day; no figures were disclosed in the notice itself.
- : electroCore submitted a 510(k) to the FDA on Oct 28, 2026 seeking clearance of its Quell device for chronic chemotherapy-induced nerve pain, backed by a 142-subject trial showing roughly 40% symptom improvement versus 24-33% for sham; the device is not yet cleared for this use.
- : On Oct 28, 2026, co-CEO Joshua Lev said electroCore is targeting positive adjusted EBITDA in the second half of 2027, aiming to get there by expanding its VA, Quell, and chemotherapy-nerve-pain opportunities; this is a stated goal, not a reported result.
- : electroCore presented at Planet MicroCap Toronto 2026 on Oct 27-29, 2026, with co-CEO Joshua Lev delivering the company presentation and hosting investor meetings.
- : On Sept 8, 2026, electroCore named Joshua Lev and Michael Fox co-CEOs following a board succession process, expanded the board to eight members, and adopted amended bylaws tightening proxy-contest advance-notice rules.
- : Sold $86K net / 11K shares through its at-the-market program, as stated for Jul 1, 2026 to Aug 6, 2026.
- : Sold $3.90M net / 495K shares through its at-the-market program, as stated for Apr 1, 2026 to Jun 30, 2026.
- : Sold $3.90M net / 495K shares through its at-the-market program, as stated for Jan 1, 2026 to Jun 30, 2026.
